[HTML][HTML] A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
HP Upadhyaya, D Desaiah, KJ Schuh, FP Bymaster… - …, 2013 - Springer
Rationale Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years
relied on psychostimulants, particularly various formulations of amphetamines and …
relied on psychostimulants, particularly various formulations of amphetamines and …
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind …
…, VK Sutton, J Gonzales, SK Malcolm, KJ Schuh… - …, 2004 - publications.aap.org
Objectives. Atomoxetine seems to be as effective for treating attention-deficit/hyperactivity
disorder (ADHD) when the daily dose is administered once in the morning as when the dose is …
disorder (ADHD) when the daily dose is administered once in the morning as when the dose is …
Desire to smoke during spaced smoking intervals
KJ Schuh, ML Stitzer - Psychopharmacology, 1995 - Springer
This study examined the detailed time course of desire to smoke self-reports during brief
periods of tobacco smoking deprivation to determine how these reports are related to amount …
periods of tobacco smoking deprivation to determine how these reports are related to amount …
Effects of buprenorphine and methadone in methadone-maintained subjects
SL Walsh, HL June, KJ Schuh, KL Preston… - …, 1995 - Springer
Buprenorphine, a partial mu opioid agonist, is an experimental medication under development
for the treatment of opioid dependence as an alternative to methadone maintenance. The …
for the treatment of opioid dependence as an alternative to methadone maintenance. The …
Validation of the adult ADHD investigator symptom rating scale (AISRS)
…, TE Brown, JA Holdnack, KJ Schuh… - Journal of Attention …, 2010 - journals.sagepub.com
… Qiao, Schuh, and Kelsey are full-time employees and minor shareholders of Lilly USA,
LLC. Dr. Trzepacz is a full-time employee and minor shareholder of Eli Lilly and Company. …
LLC. Dr. Trzepacz is a full-time employee and minor shareholder of Eli Lilly and Company. …
Caffeine reinforcement: the role of withdrawal
KJ Schuh, RR Griffiths - Psychopharmacology, 1997 - Springer
This study examined caffeine’s acute and withdrawal effects in moderate caffeine consumers
(mean = 379 mg/day caffeine) to compare the relative contributions each might have to …
(mean = 379 mg/day caffeine) to compare the relative contributions each might have to …
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder
…, GJ Emslie, CJ Kratochvil, HF Laws, KJ Schuh… - …, 2002 - publications.aap.org
Objective. The efficacy of atomoxetine was assessed in school-age girls with attention-deficit/hyperactivity
disorder (ADHD). Atomoxetine is a potent inhibitor of the presynaptic …
disorder (ADHD). Atomoxetine is a potent inhibitor of the presynaptic …
Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet
KJ Schuh, CE Johanson - Drug and alcohol dependence, 1999 - Elsevier
Buprenorphine is a μ opioid partial agonist being developed as a treatment for opioid
dependence. Buprenorphine, usually administered as a sublingual liquid, is now being developed …
dependence. Buprenorphine, usually administered as a sublingual liquid, is now being developed …
Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans
KJ Schuh, SL Walsh, ML Stitzer - Psychopharmacology, 1999 - Springer
Rationale: One therapeutic benefit of mu opioid agonist or antagonist maintenance is the
resultant attenuation of the effects of illicit opioids. It is important to characterize the …
resultant attenuation of the effects of illicit opioids. It is important to characterize the …
Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis
CR Sumner, KJ Schuh, VK Sutton, R Lipetz… - Journal of Child & …, 2006 - liebertpub.com
Introduction: Nocturnal enuresis is a condition in which children at least 5 years of age are
incontinent of urine at night. Atomoxetine, a potent inhibitor of the presynaptic norepinephrine …
incontinent of urine at night. Atomoxetine, a potent inhibitor of the presynaptic norepinephrine …